Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrimethamine/Sulfadiazine vs TMP-SMX for Toxoplasmic Encephalitis in AIDS
NCT00367081Phase 4Completed
- Sponsor
- Ministry of Public Health
- Start
- May 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of trimethoprim and sulfamethoxazole in Toxoplasmic encephalitis (TE) (3 arms), sponsored by Ministry of Public Health. Primary endpoint: Survival rate at 6 weeks. Started May 2003; status: completed.
02
Drugs
trimethoprimsulfamethoxazole
03
Conditions
Toxoplasmic encephalitis (TE)
Beyond the preview
Go deeper on NCT00367081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367081.